Spots Global Cancer Trial Database for Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Official Title: High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases

Study ID: NCT00716066

Conditions

Autoimmune Disease

Neurologic Autoimmune Disease

Autologous Transplant Autoimmune

Multiple Sclerosis Transplant

MS Stem Cell Transplant

Multiple Sclerosis Stem Cell Transplant

Stiff Person Syndrome

HCT for Neurologic Autoimmune Disorders

CIDP Transplant

Myasthenia Gravis Transplant

Autoimmune Nervous System Disorder

Central Nervous System Vasculitis

Cerebellar Degeneration

Chronic Inflammatory Demyelinating Polyneuropathy

Lambert Eaton Myasthenic Syndrome

Myasthenia Gravis

Neuromyelitis Optica

Opsoclonus Myoclonus Syndrome

Rasmussen Subacute Encephalitis

Interventions

Anti-Thymocyte Globulin

Autologous Hematopoietic Stem Cell Transplantation

Carmustine

Cytarabine

Etoposide

Laboratory Biomarker Analysis

Melphalan

Peripheral Blood Stem Cell Transplantation

Prednisone

Syngeneic Bone Marrow Transplantation

Study Description

Brief Summary: This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.

Detailed Description: OUTLINE: Patients receive carmustine intravenously (IV) on day -6, etoposide IV and cytarabine IV twice daily (BID) on days -5 to -2, melphalan IV on day -1, and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic stem cell transplant on day 0. Patients also receive prednisone orally (PO) once daily (QD) on days 7-21, followed by 2 week taper. After completion of study treatment, patients are followed up at 3 months, 1 year, and then annually thereafter for up to 5 years.